BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter ...

The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau/Files (Reuters) - U.S. generics drugmaker Mylan said on ...

Sanofi has inaugurated a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus SoloSTAR at its Beijing plant located at the Beijing Economic-Technological ...

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition. Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin ...

Mylan N.V.MYL announced that the U.S. Patent and Trademark Appeal Board ("PTAB") has instituted inter partes review ("IPR") proceedings on all claims against two Orange Book-listed patents - U.S.

PITTSBURGH, Dec. 29, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior rulings ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...